L
Luke Nordquist
Publications - 23
Citations - 1312
Luke Nordquist is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 3, co-authored 3 publications receiving 1268 citations.
Papers
More filters
Journal ArticleDOI
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli,Sherman Baker,Sarah Temin,William Pao,Timothy Aliff,Julie R. Brahmer,David H. Johnson,Janessa L. Laskin,Gregory A. Masters,Daniel T. Milton,Luke Nordquist,David G. Pfister,Steven Piantadosi,Joan H. Schiller,Reily Smith,Thomas J. Smith,John R. Strawn,David Trent,Giuseppe Giaccone +18 more
TL;DR: The scope of the guideline was narrowed to chemotherapy and biologic therapy, and recommendations for the treatment of patients with stage IV non-small-cell lung cancer were updated.
Journal ArticleDOI
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli,Sarah Temin,Timothy Aliff,Sherman Baker,Julie R. Brahmer,David H. Johnson,Janessa L. Laskin,Gregory A. Masters,Daniel T. Milton,Luke Nordquist,William Pao,David G. Pfister,Steven Piantadosi,Joan H. Schiller,Reily Smith,Thomas J. Smith,John R. Strawn,David Trent,Giuseppe Giaccone +18 more
TL;DR: This document updates one recommendation of the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy.
Journal ArticleDOI
[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].
Christopher G. Azzoli,Sherman Baker,Sarah Temin,William Pao,Timothy Aliff,Julie R. Brahmer,David H. Johnson,Janessa L. Laskin,Gregory A. Masters,Daniel T. Milton,Luke Nordquist,David G. Pfister,Steven Piantadosi,Joan H. Schiller,Reily Smith,Thomas J. Smith,John R. Strawn,David Trent,Giuseppe Giaccone +18 more
TL;DR: Author(s): Azzoli, Christopher G; Baker, Sherman; Temin, Sarah; Pao, William; Aliff, Timothy; Brahmer, Julie; Johnson, David H; Laskin, Janessa L; Masters, Gregory; Milton, Daniel; Nordquist, Luke; Pfister, David G; Piantadosi, Steven; Schiller, Joan H; Smith, Reily; Smith J; Strawn, John R.
Journal ArticleDOI
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Evan Y. Yu,Josep M. Piulats,Gwenaelle Gravis,Peter C.C. Fong,Tilman Todenhöfer,Brigitte Laguerre,Jose Angel Arranz,Stéphane Oudard,Christophe Massard,Julia Heinzelbecker,Luke Nordquist,Joan Carles,Michael Kolinsky,Marinela Augustin,Howard Gurney,Ali Tafreshi,Xin Li,Ping Qiu,Christian Heinrich Poehlein,Charles Schloss,Johann S. de Bono +20 more
TL;DR: Pembrolizumab and olaparib have shown single-agent activity in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC) as mentioned in this paper .
Journal ArticleDOI
Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.
Daniel P. Petrylak,Scott T. Tagawa,Rohit Jain,Manoj Bupathi,Arjun Vasant Balar,Arash Rezazadeh,Saby George,Phillip L. Palmbos,Luke Nordquist,Nancy B. Davis,Chethan Ramamurthy,Cora N. Sternberg,Yohann Loriot,Neeraj Agarwal,Chandler H. Park,Julia Tonelli,Morganna Vance,Hua Feng Zhou,Petros Grivas +18 more
TL;DR: Tagawa et al. as discussed by the authors reported the results of the phase 2 TROPHY-U-01 Cohort 2 study and showed that SG monotherapy demonstrated a high response rate with an overall manageable safety profile in PT-ineligible pts with locally advanced or mUC who progressed after CPI therapy.